Genetic Technologies Limited (GNTLF) 6-K 27 Feb 23 Current report (foreign) Financial data

Cover

Cover	6 Months Ended
	Dec. 31, 2022
Cover [Abstract]
Document Type	6-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2022
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2023
Current Fiscal Year End Date	--06-30
Entity File Number	0-51504
Entity Registrant Name	GENETIC TECHNOLOGIES LIMITED
Entity Central Index Key	0001166272
Entity Address, Address Line One	60-66 Hanover Street
Entity Address, City or Town	Fitzroy
Entity Address, Country	AU
Entity Address, Postal Zip Code	3065

Condensed Consolidated Statemen

Condensed Consolidated Statement of Profit or Loss and Comprehensive Income - AUD ($)	6 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Profit or loss [abstract]
Revenue from contracts with customers	$ 4,153,947	$ 2,051,016
Finance income	79,747	15,040
Other income	823,922	1,403,956
Changes in inventories	(6,527)	(257,677)
Raw materials	(2,141,158)	(871,202)
Commissions	(113,415)	(60,961)
Employee benefits expenses	(3,109,064)	(2,975,262)
Advertising and promotional expenses	(1,537,769)	(840,673)
Professional fees	(790,612)	(730,419)
Research and development expenses	(558,306)	(370,961)
Depreciation and amortisation	(330,187)	(281,304)
Impairment (expenses)/reversal	(280,725)	302
Other expenses	(1,782,292)	(958,983)
Finance costs	(15,872)	(4,243)
Loss from operations before income tax	(5,608,311)	(3,881,371)
Income tax credit	148,013
Loss for the period	(5,460,298)	(3,881,371)
Other comprehensive income Items that may be reclassified to profit or loss:
Exchange gains on translation of controlled foreign operations	15,497	7,078
Other comprehensive income for the period; net of tax	15,497	7,078
Total comprehensive loss for the period is attributable to: Owners of Genetic Technologies Limited	$ (5,444,801)	$ (3,874,293)
Loss per share for loss attributable to the ordinary equity holders of the Company:
Basic/diluted loss per share (cents per share)	$ (0.06)	$ (0.04)

Condensed Consolidated Statem_2

Condensed Consolidated Statement of Financial Position - AUD ($)	Dec. 31, 2022	Jun. 30, 2022
Current assets
Cash and cash equivalents	$ 5,045,188	$ 11,731,325
Trade and other receivables	2,931,189	2,421,238
Inventories	404,677	398,150
Other current assets	423,960	166,087
Total current assets	8,805,014	14,716,800
Non-current assets
Right-of-use assets	594,657	647,150
Property, plant and equipment	190,328	306,175
Goodwill	5,479,027	4,506,653
Other intangible assets	551,265	624,920
Deferred tax asset	74,358
Total non-current assets	6,889,635	6,084,898
Total assets	15,694,649	20,801,698
Current liabilities
Trade and other payables	2,473,592	2,122,379
Deferred income	1,053,260	814,150
Provisions	422,416	611,060
Lease liabilities	283,973	264,130
Total current liabilities	4,233,241	3,811,719
Non-current liabilities
Provisions	29,962	22,499
Lease liabilities	328,417	388,396
Deferred tax liability	74,358	148,013
Total non-current liabilities	432,737	558,908
Total liabilities	4,665,978	4,370,627
Net assets	11,028,671	16,431,071
EQUITY
Share capital	155,138,636	155,138,636
Reserves	11,556,549	11,498,651
Accumulated losses	(155,666,514)	(150,206,216)
Total equity	$ 11,028,671	$ 16,431,071

Condensed Consolidated Statem_3

Condensed Consolidated Statement of Changes in Equity - AUD ($)	Issued capital [member]	Other reserves [member]	Retained earnings [member]	Total
Balance at Jun. 30, 2021	$ 153,574,974	$ 11,033,279	$ (143,075,218)	$ 21,533,035
IfrsStatementLineItems [Line Items]
Loss for the period			(3,881,371)	(3,881,371)
Other comprehensive gain		7,078		7,078
Total comprehensive income for the half-year		7,078	(3,881,371)	(3,874,293)
Transactions with owners in their capacity as owners:
Contributions of equity, net of transaction costs and tax	1,564,912			1,564,912
Share based payments expense		227,208		227,208
Transactions with owners in their capacity as owners	1,564,912	227,208		1,792,120
Balance at Dec. 31, 2021	155,139,886	11,267,565	(146,956,589)	19,450,862
Balance at Jun. 30, 2022	155,138,636	11,498,651	(150,206,216)	16,431,071
IfrsStatementLineItems [Line Items]
Loss for the period			(5,460,298)	(5,460,298)
Other comprehensive gain		15,497		15,497
Total comprehensive income for the half-year		15,497	(5,460,298)	(5,444,801)
Transactions with owners in their capacity as owners:
Share based payments expense		333,829		333,829
Transactions with owners in their capacity as owners		42,401		42,401
Reversal of forfeited Performance Rights		(291,428)		(291,428)
Balance at Dec. 31, 2022	$ 155,138,636	$ 11,556,549	$ (155,666,514)	$ 11,028,671

Condensed Consolidated Statem_4

Condensed Consolidated Statement of Cash Flows - AUD ($)	6 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Cash flows from operating activities
Receipts from customers	$ 4,455,615	$ 2,658,872
Payments to suppliers and employees	(10,587,443)	(6,795,656)
Net cash outflow from operating activities	(6,131,828)	(4,136,784)
Cash flows from investing activities
Payments to acquire businesses	(486,187)	(3,397,959)
Payments for property, plant and equipment	(3,114)	(47,292)
Interest received	79,747	13,491
Net cash outflow from investing activities	(409,554)	(3,431,760)
Cash flows from financing activities
Lease payments	(166,484)	(15,445)
Net cash outflow from financing activities	(166,484)	(15,445)
Net decrease in cash and cash equivalents	(6,707,866)	(7,583,989)
Cash and cash equivalents at the beginning of the financial year	11,731,325	20,902,282
Effects of exchange rate changes on cash and cash equivalents	21,729	189,077
Cash and cash equivalents at end of the half-year	$ 5,045,188	$ 13,507,370

Basis of preparation of half-ye

Basis of preparation of half-year report	6 Months Ended
	Dec. 31, 2022
Basis Of Preparation Of Half-year Report
Basis of preparation of half-year report	1 Basis of preparation of half-year report This condensed consolidated interim financial report for the half-year reporting period ended 31 December 2022 have been prepared in accordance with Accounting Standard AASB 134 Interim Financial Reporting and the Corporations Act 2001. This interim report does not include all the notes of the type normally included in an annual financial report. Accordingly, this report is to be read in conjunction with the annual report for the year ended 30 June 2022 and any public announcements made by Genetic Technologies Limited during the interim reporting period in accordance with the continuous disclosure requirements of the Corporations Act 2001. The accounting policies adopted are consistent with those of the previous financial year and corresponding interim reporting period and the adoption of the new and amended standards as set out below. The Interim Financial Statements have been approved and authorised for issue by the board on 24 February 2023. The consolidated financial statements of Genetic Technologies Limited group also comply with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board (IASB). Going concern For the period ended 31 December 2022, the Company incurred a total comprehensive loss of $ 5,444,801 3,874,293 6,131,828 4,136,784 5,045,188 4,571,773 On 8 February 2023, GTG announced it had raised USD$ 5 At the date of this report, the Directors believe that the Company has sufficient cash reserves to fund its operations for at least the next 12 months. As a result, these financial statements have been prepared on a going concern basis.

Segment information

Segment information	6 Months Ended
	Dec. 31, 2022
Segment Information
Segment information	2 Segment information a. Description of segments and principal activities The Company has identified three reportable segments which is consistent with the internal reporting provided to the chief operating decision maker, the Chief Executive Officer. As of 30 June 2022, the Company changed its reportable operating segments from two geographical segments, previously Australia and USA, to two business unit segments, EasyDNA and geneType/Corporate as a result of integrating the EasyDNA acquisition in fiscal 2022. The Company changed its reporting structure to better reflect what the chief operating decision maker is reviewing to make organisational decisions and resource allocations. On 14 July 2022, a new business unit was created following the acquisition of AffinityDNA. The prior period presentation of segment information has been recast to conform with the current segment reporting structure. The three reportable segments are: ● EasyDNA: relates to EasyDNA branded test sales and expenses. ● AffinityDNA: relates to AffinityDNA branded test sales and expenses. ● geneType / Corporate: relates to geneType branded test sales and expense, including corporate charges. Genetic Technologies Limited Notes to the condensed consolidated financial statements 31 December 2022 2 Segment information (continued) b. Business unit segments The segment information for the reportable segments is as follows: Summary of reportable segments 31 December 2022 EasyDNA AffinityDNA geneType/ Corporate Total $ $ $ $ Segment revenue & other income Revenue from contracts with customers 3,813,482 330,777 9,688 4,153,947 Other income - - 823,922 823,922 Finance income - - 79,747 79,747 Total segment revenue & other income 3,813,482 330,777 913,357 5,057,616 Segment expenses Depreciation and amortisation (15,211 ) (10,521 ) (304,455 ) (330,187 ) Finance costs (1,317 ) (1,432 ) (13,123 ) (15,872 ) Raw materials and change in inventories (1,965,338 ) (155,686 ) (26,661 ) (2,147,685 ) Commissions (97,918 ) (15,497 ) - (113,415 ) Employee benefits expenses (777,593 ) (64,277 ) (2,267,194 ) (3,109,064 ) Advertising and promotional expenses (946,757 ) (13,572 ) (577,440 ) (1,537,769 ) Professional fees (1,710 ) - (788,902 ) (790,612 ) Research and development expenses - - (558,306 ) (558,306 ) Impairment reversal/(expenses) - - (280,725 ) (280,725 ) Other expenses (462,753 ) (56,973 ) (1,262,566 ) (1,782,292 ) Total segment expenses (4,268,597 ) (317,958 ) (6,079,372 ) (10,665,927 ) Income tax credit - - 148,013 148,013 Profit/(Loss) for the period (455,115 ) 12,819 (5,018,002 ) (5,460,298 ) Genetic Technologies Limited Notes to the condensed consolidated financial statements 31 December 2022 2 Segment information (continued) 31 December 2021 EasyDNA AffinityDNA geneType/ Corporate Total $ $ $ $ Segment revenue & other income Revenue from contracts with customers 2,044,152 - 6,864 2,051,016 Other income - - 1,403,956 1,403,956 Finance income - - 15,040 15,040 Total segment revenue & other income 2,044,152 - 1,425,860 3,470,012 Segment expenses Depreciation and amortisation (5,637 ) - (275,667 ) (281,304 ) Finance costs (723 ) - (3,520 ) (4,243 ) Raw materials and change in inventories (1,106,624 ) - (22,255 ) (1,128,879 ) Commissions (60,961 ) - - (60,961 ) Employee benefits expenses (579,391 ) - (2,395,871 ) (2,975,262 ) Advertising and promotional expenses (386,794 ) - (453,879 ) (840,673 ) Professional fees (20,346 ) - (710,073 ) (730,419 ) Research and development expenses - - (370,961 ) (370,961 ) Impairment reversal/(expenses) - - 302 302 Other expenses (254,775 ) - (704,208 ) (958,983 ) Total segment expenses (2,415,251 ) - (4,936,132 ) (7,351,383 ) Income tax expenses - - - - Loss for the period (371,099 ) - (3,510,272 ) (3,881,371 )

Revenue

Revenue	6 Months Ended
	Dec. 31, 2022
Revenue
Revenue	3 Revenue Summary of revenue 31 December 2022 31 December 2021 $ $ Sales of EasyDNA branded tests - point in time 3,813,482 2,044,152 Sales of AffinityDNA branded tests - point in time 330,777 - Sales of geneType branded tests - point in time 9,688 6,864 Revenue from contract with customers 4,153,947 2,051,016 Revenue recognition The Company operates facilities that provide genetic testing services and recognises revenue as follows: ● Revenues from the provision of genetic and clinical risk testing for cancer and other serious diseases under the geneType brand are recognised at a point time when the Company has provided the customer with their test results, the single performance obligation. ● Revenue from provision of genetic test direct to consumer under the EasyDNA and AffinityDNA brand is recognised at a point in time when the Company has provided the customer with their test results, the single performance obligation. Genetic Technologies Limited Notes to the condensed consolidated financial statements 31 December 2022

Equity

Equity	6 Months Ended
	Dec. 31, 2022
Equity
Equity	4 Equity a. Unquoted securities - movement in performance rights, options and warrants No 83,937,500 479,500,000 22,000,000 Summary of employee share and options plan Performance Rights Options and warrants Total Total Number Number Number $ Balance at 1 July 2021 203,937,500 1,000,932,828 1,204,870,328 10,314,324 Issue of performance rights 83,937,500 - 83,937,500 - Share based payments expense - - - 227,208 Forfeited/lapsed performance rights (15,000,000 ) - (15,000,000 ) - Performance rights exercised (7,875,000 ) - (7,875,000 ) - Forfeited/lapsed options - (22,000,000 ) (22,000,000 ) - At 31 December 2021 265,000,000 978,932,828 1,243,932,828 10,541,532 Performance Rights Options and warrants Total Total Number Number Number $ Balance at 1 July 2022 265,000,000 756,666,778 1,021,666,778 10,751,832 Share based payments expense - - - 333,829 Forfeited performance rights (40,000,000 ) - (40,000,000 ) (291,428 ) Lapsed options - (479,500,000 ) (479,500,000 ) - At 31 December 2022 225,000,000 277,166,778 502,166,778 10,794,233 b. Other reserves Summary of other reserve Share based payments Foreign currency translation Total $ $ $ Balance at 1 July 2021 10,314,324 718,955 11,033,279 Currency translation differences - 7,078 7,078 Other comprehensive income for the period - 7,078 7,078 Share based payments expense 227,208 - 227,208 Forfeited performance rights - At 31 December 2021 10,541,532 726,033 11,267,565 Share based payments Foreign currency translation Total $ $ $ Balance at 1 July 2022 10,751,832 746,819 11,498,651 Other reserve at beginning 10,751,832 746,819 11,498,651 Currency translation differences - 15,497 15,497 Other comprehensive income for the period - 15,497 15,497 Share based payments expense 333,829 - 333,829 Forfeited performance rights (291,428 ) - (291,428 ) At 31 December 2022 10,794,233 762,316 11,556,549 Other reserve at end 10,794,233 762,316 11,556,549 Genetic Technologies Limited Notes to the condensed consolidated financial statements 31 December 2022

Loss per share

Loss per share	6 Months Ended
	Dec. 31, 2022
Loss Per Share
Loss per share	5 Loss per share a. Reconciliation of earnings used in calculating earnings per share Summary of earnings per share and weighted average number of shares 31 December 2022 31 December 2021 $ $ Basic earnings per share: Loss attributable to the ordinary equity holders of the Company used in calculating basic/diluted earnings per share: From continuing operations (5,460,298 ) (3,881,371 ) b. Weighted average number of shares used as denominator 31 December 2022 31 December 2022 Number Number Weighted average number of ordinary shares used as the denominator in calculating basic and diluted loss per share * 9,233,965,143 9,206,953,433 Basic/diluted loss per share (cents per share) (0.06 ) (0.04 ) * The calculation of diluted loss per share - potential ordinary shares are considered anti-dilutive, therefore diluted loss per share is equivalent to basic loss per share.

Goodwill

Goodwill	6 Months Ended
	Dec. 31, 2022
Summary Of Changes In Goodwill
Goodwill	6 Goodwill The following table shows the movements in goodwill: Summary of changes in goodwill 31 December 2022 30 June 2022 $ $ Gross carrying amount Balance at beginning of period 4,506,653 - Goodwill gross carrying amount, balance at beginning 4,506,653 - Acquired through business combination 972,374 4,506,653 Balance at end of period 5,479,027 4,506,653 Goodwill gross carrying amount, balance at ending 5,479,027 4,506,653 Accumulated impairment Balance at beginning of period - - Goodwill accumulated impairment at beginning - - Impairment loss recognised - - Balance at end of period - - Goodwill accumulated impairment at ending - - Carrying amount at the end of the period 5,479,027 4,506,653 Genetic Technologies Limited Notes to the condensed consolidated financial statements 31 December 2022

Business acquisition

Business acquisition	6 Months Ended
	Dec. 31, 2022
Business Acquisition
Business acquisition	7 Business acquisition On 14 July 2022, the Company completed the acquisition of AffinityDNA’s direct-to-consumer eCommerce business and distribution rights. The purchase consideration has two parts, $ 486,187 277,500 486,187 277,500 The value identified in relation to the acquisition of the AffinityDNA is provisional while the Company gathers the information necessary to accurately value the intangible assets acquired via the transaction. This may impact the initial accounting for fair value of the acquired business. The fair value will be determined in conjunction with the finalisation of the full year financial results for the financial year ending 30 June 2023. Details of net assets acquired and of goodwill are as follows: Summary of business acquisition assets and goodwill acquired $ Fair value of consideration transferred Amount settled in cash 486,187 Contingent consideration 486,187 Total consideration 972,374 Recognised amounts of identifiable net assets * - Goodwill on acquisition 972,374 * All assets and liabilities of AffinityDNA were either fully settled or remained with the previous owner, which resulted in nil balance recognised on acquisition date. Goodwill arises on the acquisition of a business combination. Goodwill is calculated as the excess sum of: ● the consideration transferred; ● any non-controlling interest; and ● the acquisition date fair value of any previously held equity interest; over the acquisition date fair value of net identifiable assets acquired. Goodwill is not amortised. Instead, goodwill is tested annually for impairment, or more frequently if events or changes in circumstances indicate that it might be impaired, and is carried at cost less accumulated impairment losses. Impairment losses on goodwill are taken to profit or loss and are not subsequently reversed.

Related party transactions

Related party transactions	6 Months Ended
	Dec. 31, 2022
Related Party Transactions
Related party transactions	8 Related party transactions a. Parent entities i. Ultimate parent Genetic Technologies Limited is the ultimate Australian parent Company. As at the date of this report, no shareholder controls more than 50% of the issued capital of the Company. b. Transactions with other related parties During the half-year ended 31 December 2022, the only transactions between entities within the group and other related parties, are as listed below. Except where noted, all amounts were charged on similar to market terms and at commercial rates. i. Mr Peter Rubinstein (Non-Executive Director and Chairman) During the financial year ended June 30, 2020, the board approved the payment of consulting services to Non-Executive Director and current Chairman, Mr Peter Rubinstein for his advice relating to capital raises, compliance, NASDAQ hearings and investor relations. The services procured were through Mr Peter Rubinstein’s associate entity ValueAdmin.com Pty Ltd and during the current reporting period amounted to $ 33,000 33,000 Genetic Technologies Limited Notes to the condensed consolidated financial statements 31 December 2022 8 Related party transactions (continued) ii. Mr Stanley Sack (former Chief Operating Officer) In the comparative period, the Company engaged Mr Stanley Sack to provide consulting services via his related entity Cobben Investments in the capacity of Chief Operating Officer. The total paid to Cobben Investments during this period was $ 78,750

Events occurring after the repo

Events occurring after the reporting period	6 Months Ended
	Dec. 31, 2022
Events Occurring After Reporting Period
Events occurring after the reporting period	9 Events occurring after the reporting period On 6 February 2023, the Company announced that it had entered into definitive agreements with several institutional investors for the purchase and sale in a registered direct offering of 3,846,155 six hundred (600) ordinary shares 1.30 5 On 3 February 2023, GTG announced the launch of the first Comprehensive Risk Test for Breast & Ovarian Cancer. The test evaluates a woman’s risk of developing Breast and/or Ovarian Cancer either from a hereditary genetic mutation or from the far more common familial or sporadic cancer. In combination with other clinical risk factors, the test provides a comprehensive risk assessment in a simple saliva test. On 1 February 2023, the Company announced the intention to form a strategic alliance with QIAGEN, a global leader in molecular testing with operations in 35 countries. The alliance will establish and develop a ‘Centre of Excellence’ facility in Australia initially servicing Australia and New Zealand with potential for expansion, showcasing the Life Science and Diagnostics expertise of both organizations throughout the region. The partnership will further enhance GTG’s reputation as a regional leader in precision medicine in predicative and consumer genomics, utilizing QIAGEN technologies. The relationship is expected to open a wide range of new commercial opportunities for GTG with enhanced automation capability and increased capacity supporting long-term revenue growth. Additionally, this initiative will unlock the Australian reimbursable market for various testing categories, including the geneType hereditary cancer test. This will make the geneType Breast, Ovarian and Colorectal cancer tests the most comprehensive offering in the market later in 2023. Except for the above, no matter or circumstance has occurred subsequent to period end that has significantly affected, or may significantly affect, the operations of the group, the results of those operations or the state of affairs of the group or economic entity in subsequent financial periods.

Segment information (Tables)

Segment information (Tables)	6 Months Ended
	Dec. 31, 2022
Segment Information
Summary of reportable segments	The segment information for the reportable segments is as follows: Summary of reportable segments 31 December 2022 EasyDNA AffinityDNA geneType/ Corporate Total $ $ $ $ Segment revenue & other income Revenue from contracts with customers 3,813,482 330,777 9,688 4,153,947 Other income - - 823,922 823,922 Finance income - - 79,747 79,747 Total segment revenue & other income 3,813,482 330,777 913,357 5,057,616 Segment expenses Depreciation and amortisation (15,211 ) (10,521 ) (304,455 ) (330,187 ) Finance costs (1,317 ) (1,432 ) (13,123 ) (15,872 ) Raw materials and change in inventories (1,965,338 ) (155,686 ) (26,661 ) (2,147,685 ) Commissions (97,918 ) (15,497 ) - (113,415 ) Employee benefits expenses (777,593 ) (64,277 ) (2,267,194 ) (3,109,064 ) Advertising and promotional expenses (946,757 ) (13,572 ) (577,440 ) (1,537,769 ) Professional fees (1,710 ) - (788,902 ) (790,612 ) Research and development expenses - - (558,306 ) (558,306 ) Impairment reversal/(expenses) - - (280,725 ) (280,725 ) Other expenses (462,753 ) (56,973 ) (1,262,566 ) (1,782,292 ) Total segment expenses (4,268,597 ) (317,958 ) (6,079,372 ) (10,665,927 ) Income tax credit - - 148,013 148,013 Profit/(Loss) for the period (455,115 ) 12,819 (5,018,002 ) (5,460,298 ) Genetic Technologies Limited Notes to the condensed consolidated financial statements 31 December 2022 2 Segment information (continued) 31 December 2021 EasyDNA AffinityDNA geneType/ Corporate Total $ $ $ $ Segment revenue & other income Revenue from contracts with customers 2,044,152 - 6,864 2,051,016 Other income - - 1,403,956 1,403,956 Finance income - - 15,040 15,040 Total segment revenue & other income 2,044,152 - 1,425,860 3,470,012 Segment expenses Depreciation and amortisation (5,637 ) - (275,667 ) (281,304 ) Finance costs (723 ) - (3,520 ) (4,243 ) Raw materials and change in inventories (1,106,624 ) - (22,255 ) (1,128,879 ) Commissions (60,961 ) - - (60,961 ) Employee benefits expenses (579,391 ) - (2,395,871 ) (2,975,262 ) Advertising and promotional expenses (386,794 ) - (453,879 ) (840,673 ) Professional fees (20,346 ) - (710,073 ) (730,419 ) Research and development expenses - - (370,961 ) (370,961 ) Impairment reversal/(expenses) - - 302 302 Other expenses (254,775 ) - (704,208 ) (958,983 ) Total segment expenses (2,415,251 ) - (4,936,132 ) (7,351,383 ) Income tax expenses - - - - Loss for the period (371,099 ) - (3,510,272 ) (3,881,371 )

Revenue (Tables)

Revenue (Tables)	6 Months Ended
	Dec. 31, 2022
Revenue
Summary of revenue	Summary of revenue 31 December 2022 31 December 2021 $ $ Sales of EasyDNA branded tests - point in time 3,813,482 2,044,152 Sales of AffinityDNA branded tests - point in time 330,777 - Sales of geneType branded tests - point in time 9,688 6,864 Revenue from contract with customers 4,153,947 2,051,016

Equity (Tables)

Equity (Tables)	6 Months Ended
	Dec. 31, 2022
Equity
Summary of employee share and options plan	Summary of employee share and options plan Performance Rights Options and warrants Total Total Number Number Number $ Balance at 1 July 2021 203,937,500 1,000,932,828 1,204,870,328 10,314,324 Issue of performance rights 83,937,500 - 83,937,500 - Share based payments expense - - - 227,208 Forfeited/lapsed performance rights (15,000,000 ) - (15,000,000 ) - Performance rights exercised (7,875,000 ) - (7,875,000 ) - Forfeited/lapsed options - (22,000,000 ) (22,000,000 ) - At 31 December 2021 265,000,000 978,932,828 1,243,932,828 10,541,532 Performance Rights Options and warrants Total Total Number Number Number $ Balance at 1 July 2022 265,000,000 756,666,778 1,021,666,778 10,751,832 Share based payments expense - - - 333,829 Forfeited performance rights (40,000,000 ) - (40,000,000 ) (291,428 ) Lapsed options - (479,500,000 ) (479,500,000 ) - At 31 December 2022 225,000,000 277,166,778 502,166,778 10,794,233
Summary of other reserve	Summary of other reserve Share based payments Foreign currency translation Total $ $ $ Balance at 1 July 2021 10,314,324 718,955 11,033,279 Currency translation differences - 7,078 7,078 Other comprehensive income for the period - 7,078 7,078 Share based payments expense 227,208 - 227,208 Forfeited performance rights - At 31 December 2021 10,541,532 726,033 11,267,565 Share based payments Foreign currency translation Total $ $ $ Balance at 1 July 2022 10,751,832 746,819 11,498,651 Other reserve at beginning 10,751,832 746,819 11,498,651 Currency translation differences - 15,497 15,497 Other comprehensive income for the period - 15,497 15,497 Share based payments expense 333,829 - 333,829 Forfeited performance rights (291,428 ) - (291,428 ) At 31 December 2022 10,794,233 762,316 11,556,549 Other reserve at end 10,794,233 762,316 11,556,549

Loss per share (Tables)

Loss per share (Tables)	6 Months Ended
	Dec. 31, 2022
Loss Per Share
Summary of earnings per share and weighted average number of shares	a. Reconciliation of earnings used in calculating earnings per share Summary of earnings per share and weighted average number of shares 31 December 2022 31 December 2021 $ $ Basic earnings per share: Loss attributable to the ordinary equity holders of the Company used in calculating basic/diluted earnings per share: From continuing operations (5,460,298 ) (3,881,371 ) b. Weighted average number of shares used as denominator 31 December 2022 31 December 2022 Number Number Weighted average number of ordinary shares used as the denominator in calculating basic and diluted loss per share * 9,233,965,143 9,206,953,433 Basic/diluted loss per share (cents per share) (0.06 ) (0.04 ) * The calculation of diluted loss per share - potential ordinary shares are considered anti-dilutive, therefore diluted loss per share is equivalent to basic loss per share.

Goodwill (Tables)

Goodwill (Tables)	6 Months Ended
	Dec. 31, 2022
Summary Of Changes In Goodwill
Summary of changes in goodwill	The following table shows the movements in goodwill: Summary of changes in goodwill 31 December 2022 30 June 2022 $ $ Gross carrying amount Balance at beginning of period 4,506,653 - Goodwill gross carrying amount, balance at beginning 4,506,653 - Acquired through business combination 972,374 4,506,653 Balance at end of period 5,479,027 4,506,653 Goodwill gross carrying amount, balance at ending 5,479,027 4,506,653 Accumulated impairment Balance at beginning of period - - Goodwill accumulated impairment at beginning - - Impairment loss recognised - - Balance at end of period - - Goodwill accumulated impairment at ending - - Carrying amount at the end of the period 5,479,027 4,506,653

Business acquisition (Tables)

Business acquisition (Tables)	6 Months Ended
	Dec. 31, 2022
Business Acquisition
Summary of business acquisition assets and goodwill acquired	Details of net assets acquired and of goodwill are as follows: Summary of business acquisition assets and goodwill acquired $ Fair value of consideration transferred Amount settled in cash 486,187 Contingent consideration 486,187 Total consideration 972,374 Recognised amounts of identifiable net assets * - Goodwill on acquisition 972,374 * All assets and liabilities of AffinityDNA were either fully settled or remained with the previous owner, which resulted in nil balance recognised on acquisition date.

Basis of preparation of half-_2

Basis of preparation of half-year report (Details Narrative) - AUD ($)	6 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Feb. 08, 2023	Jun. 30, 2022	Jun. 30, 2021
IfrsStatementLineItems [Line Items]
Total comprehensive loss	$ 5,444,801	$ 3,874,293
Net cash outflow from operations	6,131,828	4,136,784
Total cash and cash equivalents	5,045,188	$ 13,507,370		$ 11,731,325	$ 20,902,282
Total net current assets	4,571,773
New capital	$ 155,138,636			$ 155,138,636
Nonadjusting Event [Member]
IfrsStatementLineItems [Line Items]
New capital			$ 5,000,000

Summary of reportable segments

Summary of reportable segments (Details) - AUD ($)	6 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
IfrsStatementLineItems [Line Items]
Revenue from contracts with customers	$ 4,153,947	$ 2,051,016
Other income	823,922	1,403,956
Finance income	79,747	15,040
Total segment revenue & other income	5,057,616	3,470,012
Depreciation and amortisation	(330,187)	(281,304)
Finance costs	(15,872)	(4,243)
Raw materials and change in inventories	(2,147,685)	(1,128,879)
Commissions	(113,415)	(60,961)
Employee benefits expenses	(3,109,064)	(2,975,262)
Advertising and promotional expenses	(1,537,769)	(840,673)
Professional fees	(790,612)	(730,419)
Research and development expenses	(558,306)	(370,961)
Impairment reversal/(expenses)	(280,725)	302
Other expenses	(1,782,292)	(958,983)
Total segment expenses	(10,665,927)	(7,351,383)
Income tax expenses	148,013
Loss for the period	(5,460,298)	(3,881,371)
EasyDNA [Member]
IfrsStatementLineItems [Line Items]
Revenue from contracts with customers	3,813,482	2,044,152
Other income
Finance income
Total segment revenue & other income	3,813,482	2,044,152
Depreciation and amortisation	(15,211)	(5,637)
Finance costs	(1,317)	(723)
Raw materials and change in inventories	(1,965,338)	(1,106,624)
Commissions	(97,918)	(60,961)
Employee benefits expenses	(777,593)	(579,391)
Advertising and promotional expenses	(946,757)	(386,794)
Professional fees	(1,710)	(20,346)
Research and development expenses
Impairment reversal/(expenses)
Other expenses	(462,753)	(254,775)
Total segment expenses	(4,268,597)	(2,415,251)
Income tax expenses
Loss for the period	(455,115)	(371,099)
Affinity DNA [Member]
IfrsStatementLineItems [Line Items]
Revenue from contracts with customers	330,777
Other income
Finance income
Total segment revenue & other income	330,777
Depreciation and amortisation	(10,521)
Finance costs	(1,432)
Raw materials and change in inventories	(155,686)
Commissions	(15,497)
Employee benefits expenses	(64,277)
Advertising and promotional expenses	(13,572)
Professional fees
Research and development expenses
Impairment reversal/(expenses)
Other expenses	(56,973)
Total segment expenses	(317,958)
Income tax expenses
Loss for the period	12,819
GeneType/Corporate [Member]
IfrsStatementLineItems [Line Items]
Revenue from contracts with customers	9,688	6,864
Other income	823,922	1,403,956
Finance income	79,747	15,040
Total segment revenue & other income	913,357	1,425,860
Depreciation and amortisation	(304,455)	(275,667)
Finance costs	(13,123)	(3,520)
Raw materials and change in inventories	(26,661)	(22,255)
Commissions
Employee benefits expenses	(2,267,194)	(2,395,871)
Advertising and promotional expenses	(577,440)	(453,879)
Professional fees	(788,902)	(710,073)
Research and development expenses	(558,306)	(370,961)
Impairment reversal/(expenses)	(280,725)	302
Other expenses	(1,262,566)	(704,208)
Total segment expenses	(6,079,372)	(4,936,132)
Income tax expenses	148,013
Loss for the period	$ (5,018,002)	$ (3,510,272)

Summary of revenue (Details)

Summary of revenue (Details) - AUD ($)	6 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
IfrsStatementLineItems [Line Items]
Revenue from contract with customers	$ 4,153,947	$ 2,051,016
EasyDNA Branded Tests [Member] | Goods or services transferred at point in time [member]
IfrsStatementLineItems [Line Items]
Revenue from contract with customers	3,813,482	2,044,152
AffinityDNA Branded Tests [Member] | Goods or services transferred at point in time [member]
IfrsStatementLineItems [Line Items]
Revenue from contract with customers	330,777
geneType Branded Tests [Member] | Goods or services transferred at point in time [member]
IfrsStatementLineItems [Line Items]
Revenue from contract with customers	$ 9,688	$ 6,864

Summary of employee share and o

Summary of employee share and options plan (Details)	6 Months Ended
	Dec. 31, 2022 shares Integer	Dec. 31, 2021 shares Integer
IfrsStatementLineItems [Line Items]
Performance rights, options and warrants, beginning balance | Integer	10,751,832	10,314,324
Issue of performance rights | Integer
Share based payments expense | Integer	333,829	227,208
Forfeited performance rights | Integer	(291,428)
Performance rights exercised | Integer
Lapsed options | Integer
Performance rights, options and warrants, ending balance | Integer	10,794,233	10,541,532
Performance Rights [Member]
IfrsStatementLineItems [Line Items]
Performance rights, options and warrants, beginning balance	265,000,000	203,937,500
Issue of performance rights	0	83,937,500
Share based payments expense
Forfeited performance rights	(40,000,000)	(15,000,000)
Performance rights exercised		(7,875,000)
Lapsed options
Performance rights, options and warrants, ending balance	225,000,000	265,000,000
Options And Warrants [Member]
IfrsStatementLineItems [Line Items]
Performance rights, options and warrants, beginning balance	756,666,778	1,000,932,828
Issue of performance rights
Share based payments expense
Forfeited performance rights
Performance rights exercised
Lapsed options	(479,500,000)	(22,000,000)
Performance rights, options and warrants, ending balance	277,166,778	978,932,828
Performance Rights And Options And Warrants [Member]
IfrsStatementLineItems [Line Items]
Performance rights, options and warrants, beginning balance	1,021,666,778	1,204,870,328
Issue of performance rights		83,937,500
Share based payments expense
Forfeited performance rights	(40,000,000)	(15,000,000)
Performance rights exercised		(7,875,000)
Lapsed options	(479,500,000)	(22,000,000)
Performance rights, options and warrants, ending balance	502,166,778	1,243,932,828

Summary of other reserve (Detai

Summary of other reserve (Details) - AUD ($)	6 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
IfrsStatementLineItems [Line Items]
Other reserve at beginning	$ 11,498,651	$ 11,033,279
Currency translation differences	15,497	7,078
Other comprehensive income for the period	15,497	7,078
Share based payments expense	333,829	227,208
Forfeited performance rights	(291,428)
Other reserve at end	11,556,549	11,267,565
Reserve of share-based payments [member]
IfrsStatementLineItems [Line Items]
Other reserve at beginning	10,751,832	10,314,324
Currency translation differences
Other comprehensive income for the period
Share based payments expense	333,829	227,208
Forfeited performance rights	(291,428)
Other reserve at end	10,794,233	10,541,532
Foreign Currency Translation [Member]
IfrsStatementLineItems [Line Items]
Other reserve at beginning	746,819	718,955
Currency translation differences	15,497	7,078
Other comprehensive income for the period	15,497	7,078
Share based payments expense
Forfeited performance rights
Other reserve at end	$ 762,316	$ 726,033

Equity (Details Narrative)

Equity (Details Narrative)	6 Months Ended
	Dec. 31, 2022 shares Integer	Dec. 31, 2021 shares Integer
IfrsStatementLineItems [Line Items]
Issue of performance rights | Integer
Options lapsed | Integer
Performance Rights [Member]
IfrsStatementLineItems [Line Items]
Issue of performance rights	0	83,937,500
Options lapsed
Options And Warrants [Member]
IfrsStatementLineItems [Line Items]
Issue of performance rights
Options lapsed	479,500,000	22,000,000

Summary of earnings per share a

Summary of earnings per share and weighted average number of shares (Details) - AUD ($)		6 Months Ended
		Dec. 31, 2022	Dec. 31, 2021
Loss Per Share
Basic earnings per share: Loss attributable to the ordinary equity holders of the Company used in calculating basic/diluted earnings per share: From continuing operations		$ (5,460,298)	$ (3,881,371)
Weighted average number of ordinary shares used as the denominator in calculating basic and diluted loss per share	[1]	9,233,965,143	9,206,953,433
Basic/diluted loss per share (cents per share)		$ (0.06)	$ (0.04)
[1]The calculation of diluted loss per share - potential ordinary shares are considered anti-dilutive, therefore diluted loss per share is equivalent to basic loss per share.

Summary of changes in goodwill

Summary of changes in goodwill (Details) - AUD ($)	6 Months Ended	12 Months Ended
	Dec. 31, 2022	Jun. 30, 2022
Summary Of Changes In Goodwill
Goodwill gross carrying amount, balance at beginning	$ 4,506,653
Acquired through business combination	972,374	4,506,653
Goodwill gross carrying amount, balance at ending	5,479,027	4,506,653
Goodwill accumulated impairment at beginning
Impairment loss recognised
Goodwill accumulated impairment at ending
Carrying amount at the end of the period	$ 5,479,027	$ 4,506,653

Summary of business acquisition

Summary of business acquisition assets and goodwill acquired (Details) - Jul. 14, 2022 - Affinity DNA [Member]		AUD ($)	EUR (€)
IfrsStatementLineItems [Line Items]
Amount settled in cash		$ 486,187	€ 277,500
Contingent consideration		486,187	€ 277,500
Total consideration		972,374
Recognised amounts of identifiable net assets	[1]
Goodwill on acquisition		$ 972,374
[1]All assets and liabilities of AffinityDNA were either fully settled or remained with the previous owner, which resulted in nil balance recognised on acquisition date.

Business acquisition (Details N

Business acquisition (Details Narrative) - Jul. 14, 2022 - Affinity DNA [Member]	AUD ($)	EUR (€)
IfrsStatementLineItems [Line Items]
Purchase consideration	$ 486,187	€ 277,500
Contingent consideration	$ 486,187	€ 277,500

Related party transactions (Det

Related party transactions (Details Narrative) - AUD ($)	6 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Mr Peter Rubinstein [Member]
IfrsStatementLineItems [Line Items]
Services received, related party transactions	$ 33,000	$ 33,000
Mr. Stanley Sack [Member]
IfrsStatementLineItems [Line Items]
Services received, related party transactions	$ 78,750

Events occurring after the re_2

Events occurring after the reporting period (Details Narrative) $ / shares in Units, $ in Millions			6 Months Ended
	Feb. 08, 2023 USD ($)	Feb. 06, 2023 $ / shares shares	Dec. 31, 2021 AUD ($)
IfrsStatementLineItems [Line Items]
Registered direct offering, value			$ 1,564,912
Nonadjusting Events After Reporting Period [Member]
IfrsStatementLineItems [Line Items]
Registered direct offering | shares		3,846,155
Registered direct offering		six hundred (600) ordinary shares
Share price | $ / shares		$ 1.30
Registered direct offering, value	$ 5